Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
A panel of medical experts explore how to evaluate and adjust rheumatoid arthritis treatment by adhering to ACR guidelines for conventional synthetic DMARDs and advanced therapies, focusing on optimizing patient care and treatment outcomes.
EP: 1.Intro and Welcomes
EP: 2.Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission
EP: 3.Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice
EP: 4.Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis
EP: 5.Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
EP: 6.Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments
EP: 7.Achieving Low Disease Activity and Remission: Managing Patient Expectations
EP: 8.Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
EP: 9.Advanced Treatment Options for RA: Exploring the Data
EP: 10.Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
Video content above is prompted by the following:
Conventional synthetic disease-modifying antirheumatic drugs (csDMARDS), including methotrexate, are generally considered first-line treatment.The American College of Rheumatology (ACR) Guidelines recommend monitoring disease activity at least every 3 months, based on the safety and efficacy of the chosen therapy, and adjusting therapy as needed in the absence of improvement. For patients with ongoing active disease or with poor prognostic factors, combination DMARD therapy or advanced treatment with a biologic agent is typically initiated.
In your practice, how do you assess rheumatoid arthritis disease activity and therapeutic response?
